Leukemia & Lymphoma最新文献_第9页

Unusually indolent CML: a stable non-responder without complete cytogenetic remission for 30 years including 17 years on tyrosine kinase inhibitor therapy. 异常惰性CML：稳定无反应，30年未完全细胞遗传学缓解，包括17年酪氨酸激酶抑制剂治疗。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-05-01 Epub Date: 2025-01-12 DOI: 10.1080/10428194.2024.2448716

Qiudan Shen, Guilin Tang, Fadi G Haddad, Wenbo Chen, Wei J Wang, Wei Wang, Qing Wei, L Jeffrey Medeiros, Shimin Hu

引用次数: 0

Nodular lymphocyte-predominant Hodgkin lymphoma revisited: current management strategies and future perspectives. 重新审视结节淋巴细胞为主的霍奇金淋巴瘤：当前的管理策略和未来的展望。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-05-01 Epub Date: 2025-01-02 DOI: 10.1080/10428194.2024.2447886

Dennis A Eichenauer, Peter Borchmann

引用次数: 0

Outcome of extra-nodal follicular lymphoma affected by choice of induction chemoimmunotherapy and maintenance rituximab - real-world retrospective study. 结外滤泡性淋巴瘤的预后受诱导化学免疫治疗和维持利妥昔单抗选择的影响-现实世界回顾性研究。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-05-01 Epub Date: 2024-12-28 DOI: 10.1080/10428194.2024.2446615

Lawrence Cheng Kiat Ng, Shin Yeu Ong, Xinxin Huang, Aditi Ghosh, Chandramouli Nagarajan, Yeow Tee Goh, Yunxin Chen, Francesca Lorraine Wei Inng Lim, Melinda Si Yun Tan, Xiu Hue Lee, Jing Yuan Tan, Nicholas Francis Grigoropoulos, Valerie Shiwen Yang, Joshua Tian Ming Hoe, Jianbang Chiang, Esther Wei Yin Chang, Eileen Yi Ling Poon, Ya Hwee Tan, Nagavalli Somasundaram, Miriam Tao, Soon Thye Lim, Jason Yongsheng Chan

{"title":"Outcome of extra-nodal follicular lymphoma affected by choice of induction chemoimmunotherapy and maintenance rituximab - real-world retrospective study.","authors":"Lawrence Cheng Kiat Ng, Shin Yeu Ong, Xinxin Huang, Aditi Ghosh, Chandramouli Nagarajan, Yeow Tee Goh, Yunxin Chen, Francesca Lorraine Wei Inng Lim, Melinda Si Yun Tan, Xiu Hue Lee, Jing Yuan Tan, Nicholas Francis Grigoropoulos, Valerie Shiwen Yang, Joshua Tian Ming Hoe, Jianbang Chiang, Esther Wei Yin Chang, Eileen Yi Ling Poon, Ya Hwee Tan, Nagavalli Somasundaram, Miriam Tao, Soon Thye Lim, Jason Yongsheng Chan","doi":"10.1080/10428194.2024.2446615","DOIUrl":"10.1080/10428194.2024.2446615","url":null,"abstract":"The importance of extra-nodal disease has been well recognized in follicular lymphoma, and is incorporated into various prognostic tools. However, the optimal treatment strategy for this subgroup remains unclear. In this multicenter retrospective study, we analyzed 143 patients who received either R-CHOP or Bendamustine-Rituximab (BR), with a median follow-up of 69.7 months. Our findings indicate that extra-nodal disease confers poorer PFS (5-year PFS 58% vs 66%, p = 0.03) while high-risk relapse predict poorer OS (5-year OS 56% vs 94%, p < 0.001). Subgroup analysis on 98 patients with extra-nodal disease revealed that BR induction conferred superior PFS compared to R-CHOP (HR 0.49, p = 0.032) while maintenance rituximab also improved PFS (HR 0.44, p = 0.033). Patients who received R-CHOP without maintenance rituximab had significantly worse PFS (5-year PFS 41% vs 68%, p = 0.005) and OS (5-year OS 83% vs 100%, p = 0.007) compared to those with maintenance rituximab. Role of maintenance rituximab post BR remained unclear. In this retrospective study of follicular lymphoma patients with extra-nodal disease, BR induction yielded favorable PFS compared to R-CHOP and could be a preferred treatment approach. Maintenance rituximab after R-CHOP significantly improve PFS and OS and should be considered in all appropriate patients.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"906-912"},"PeriodicalIF":2.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142895914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic factors in chronic lymphocytic leukaemia - the old, the new and the future. 慢性淋巴细胞白血病的预后因素-旧的，新的和未来。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-05-01 Epub Date: 2025-01-07 DOI: 10.1080/10428194.2024.2449214

Sean McKeague, Constantine Tam

引用次数: 0

Identification of possible drug treatment targets and related immune cell infiltration properties in acute myeloid leukemia utilizing robust rank aggregation algorithm. 利用鲁棒秩聚集算法识别急性髓系白血病可能的药物治疗靶点和相关免疫细胞浸润特性

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-05-01 Epub Date: 2025-01-15 DOI: 10.1080/10428194.2025.2451064

Hengzhou Zhu, Chencen Zhang, Lei Huang, Baonan Zhang, Xiaona Huang, Jianliang You, Chunhui Jin

{"title":"Identification of possible drug treatment targets and related immune cell infiltration properties in acute myeloid leukemia utilizing robust rank aggregation algorithm.","authors":"Hengzhou Zhu, Chencen Zhang, Lei Huang, Baonan Zhang, Xiaona Huang, Jianliang You, Chunhui Jin","doi":"10.1080/10428194.2025.2451064","DOIUrl":"10.1080/10428194.2025.2451064","url":null,"abstract":"In this study, we aimed to uncover novel biomarkers in acute myeloid leukemia (AML) that could serve as prognostic indicators or therapeutic targets. We analyzed AML microarray datasets from the Gene Expression Omnibus (GEO) repository, identifying key differentially expressed genes (DEGs) through the robust rank aggregation (RRA) approach. The functions of these DEGs were elucidated through Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. Additionally, the CIBERSORT algorithm was employed to assess immune cell infiltration in AML. Six hub genes were identified using the cytoHubba plugin, and their clinical significance, survival impact, and meta-analyses were conducted. Through comprehensive bioinformatics and qPCR analyses, we gained new insights into AML pathogenesis and metastasis, identifying FCGR3B, FLT3, EREG, and MMP9 as potential prognostic biomarkers. Antagonists targeting FCGR3B, FLT3, and MMP9, or agonists for EREG, hold promise as therapeutic and preventative strategies for AML.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"930-941"},"PeriodicalIF":2.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143007615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Consistency of the efficacy of immunotherapy with histamine dihydrochloride and low-dose interleukin-2 for relapse prevention in acute myeloid leukemia. 盐酸组胺与低剂量白细胞介素-2免疫治疗预防急性髓系白血病复发疗效的一致性。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-05-01 Epub Date: 2024-12-24 DOI: 10.1080/10428194.2024.2444466

Malin S Nilsson, Anna Martner, Lovisa Wennström, Markus Hansson, Fredrik B Thorén, Kristoffer Hellstrand

引用次数: 0

Bruton's tyrosine kinase inhibitor zanubrutinib-based regimens in relapsed/refractory primary diffuse large B-cell lymphoma of the central nervous system. 基于Bruton酪氨酸激酶抑制剂zanubrutinib的方案治疗复发/难治性中枢神经系统原发性弥漫性大b细胞淋巴瘤

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-05-01 Epub Date: 2025-01-17 DOI: 10.1080/10428194.2025.2451066

Yali Wang, Jiefei Han, Shuo Yin, Shoubo Yang, Xun Kang, Xiaohong Zheng, Ling Duan, Shenglan Li, Bo Jiang, Wenbin Li, Feng Chen

{"title":"Bruton's tyrosine kinase inhibitor zanubrutinib-based regimens in relapsed/refractory primary diffuse large B-cell lymphoma of the central nervous system.","authors":"Yali Wang, Jiefei Han, Shuo Yin, Shoubo Yang, Xun Kang, Xiaohong Zheng, Ling Duan, Shenglan Li, Bo Jiang, Wenbin Li, Feng Chen","doi":"10.1080/10428194.2025.2451066","DOIUrl":"10.1080/10428194.2025.2451066","url":null,"abstract":"Patients with relapsed/refractory primary central nervous system lymphoma (R/R PCNSL) usually have a poor prognosis and limited treatment options. We respectively reviewed 38 patients with R/R PCNSL treated with zanubrutinib-based regimens in our center. The overall response rate, complete response rate and disease control rate were 76.3%, 47.4% and 92.1%, respectively. The median progression-free survival (PFS) was 31.0 months, the median overall survival (OS) was not reached. Unitivariate analysis by Cox's proportional hazards model revealed that overall response (vs. no response, HR = 0.18, 95%CI:0.07,0.48, p = 0.001), long duration of zanubrutinib (≥6months vs 2-5 months, HR = 0.20, 95%CI:0.06,0.63, p = 0.006) were independent factors for prolonged PFS. The log-rank analysis indicated a prolongation of PFS among patients exhibiting a higher Tumor mutational burden (TMB, ≥14.75muts/Mb) following zanubrutinib-based treatment (p = 0.016). Our data showed promising efficacy with tolerable safety of zanubrutinib-based therapies in patients with R/R PCNSL. Long duration of zanubrutinib may be associated with prolonged PFS.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"869-878"},"PeriodicalIF":2.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143007898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chemotherapy-free approach with arsenic trioxide and all-trans retinoic acid in children with acute promyelocytic leukemia. 三氧化二砷和全反式维甲酸治疗急性早幼粒细胞白血病儿童的无化疗方法。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-05-01 Epub Date: 2024-12-28 DOI: 10.1080/10428194.2024.2445701

Georgia Avgerinou, Elena E Solomou, Maria Filippidou, Foteini Perganti, Kleoniki Roka, Efthymia Rigatou, Katerina Katsibardi, Stavros Glentis, Antonia Vlachou, Ilona Binenbaum, Antonis Kattamis

引用次数: 0

Variance in development of early and late cardiotoxicities in patients with lymphoma and myeloma receiving CAR T-cell therapies. 接受CAR - t细胞治疗的淋巴瘤和骨髓瘤患者早期和晚期心脏毒性发展的差异

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-05-01 Epub Date: 2025-01-07 DOI: 10.1080/10428194.2024.2448713

Eli Grunblatt, Zhiying Meng, Abigail S Baldridge, Nikita P Patel, Alexander Stanisic, Matthew J Feinstein, Anjali Rao, Leo I Gordon, Jane N Winter, Shuo Ma, Jayesh Mehta, Seema Singhal, Reem Karmali, Nausheen Akhter

{"title":"Variance in development of early and late cardiotoxicities in patients with lymphoma and myeloma receiving CAR T-cell therapies.","authors":"Eli Grunblatt, Zhiying Meng, Abigail S Baldridge, Nikita P Patel, Alexander Stanisic, Matthew J Feinstein, Anjali Rao, Leo I Gordon, Jane N Winter, Shuo Ma, Jayesh Mehta, Seema Singhal, Reem Karmali, Nausheen Akhter","doi":"10.1080/10428194.2024.2448713","DOIUrl":"10.1080/10428194.2024.2448713","url":null,"abstract":"Cardiovascular adverse events (CVAEs) are recognized complications of chimeric antigen receptor (CAR) T-cell therapies. However, data are lacking regarding subtypes of adverse events that develop in patients with different malignancies, and little is known about the timeframe in which different cardiotoxicities are most likely to occur post-CAR T-cell therapies. In this study, 211 patients, including 138 lymphoma patients and 66 myeloma patients who received CAR T-cell therapies were retrospectively identified. Of these, 42 patients (19.9%) developed CVAEs post-treatment. Myeloma patients predominantly experienced heart failure while lymphoma patients predominantly experienced arrhythmia. Severe CVAEs were observed even at >12 months post-treatment. Lower baseline global longitudinal strain was significantly associated with development of post-CAR T-cell therapy CVAEs in both lymphoma and myeloma patients. These findings highlight the spectra of post-CAR T-cell cardiotoxicities in lymphoma and myeloma patients and the importance of echocardiography for pretreatment risk stratification and long-term surveillance.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"858-868"},"PeriodicalIF":2.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142950872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Significance of cycle 1 bone marrow biopsy in predicting outcomes and toxicities of venetoclax-based therapy for myeloid malignancies. 第1周期骨髓活检在预测髓系恶性肿瘤以维托克拉克斯为基础的治疗结果和毒性中的意义。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-05-01 Epub Date: 2024-12-27 DOI: 10.1080/10428194.2024.2444480

Jeffrey Baron, Daniel Appiah, Mark G Faber, Han Yu, Tara Cronin, Jared Vega, Samantha Poblete, Pamela J Sung, Elizabeth A Griffiths, Amanda Przespolewski, James E Thompson, Steven Green, Eunice S Wang

{"title":"Significance of cycle 1 bone marrow biopsy in predicting outcomes and toxicities of venetoclax-based therapy for myeloid malignancies.","authors":"Jeffrey Baron, Daniel Appiah, Mark G Faber, Han Yu, Tara Cronin, Jared Vega, Samantha Poblete, Pamela J Sung, Elizabeth A Griffiths, Amanda Przespolewski, James E Thompson, Steven Green, Eunice S Wang","doi":"10.1080/10428194.2024.2444480","DOIUrl":"10.1080/10428194.2024.2444480","url":null,"abstract":"For older unfit patients receiving venetoclax-based induction, data on the significance of interim bone marrow biopies (BMBx) findings on clinical outcomes is lacking. We retrospectively evaluated interim BMBx results performed on Cycle 1 days 21-28 of venetoclax-based therapy in 69 adults with myeloid malignancies to determine whether blast clearance was associated with overall survival (OS) and overall response rate (ORR). Median age was 75 years (range 69-78). Results demonstrated blast reduction (BR, <5% blasts) in 71%. Venetoclax was held to allow count recovery in 86% of these patients. Achieving interim BMBx BR was significantly associated with OS (p = 0.0033) and ORR (Cohen's kappa 0.39). Patients whose venetoclax was held experienced low rates of infection and reduced cytopenias. These findings support the importance of cycle 1 BMBx assessment during venetoclax-based therapies, specifically in predicting which patients will achieve optimal outcomes and in mitigating toxicity.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"913-919"},"PeriodicalIF":2.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12143198/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142895922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0